Renal Cancer - Results from #1900

Partial versus radical nephrectomy in clinical T2 renal masses. August 16, 2021

Feasibility and Outcomes of Renal Mass Biopsy for Anatomically Complex Renal Tumors. August 13, 2021

The financial impact of cancer care on renal cancer patients. August 13, 2021

FDA Approves Pembrolizumab plus Lenvatinib Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC) August 12, 2021

Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. August 12, 2021

Can preoperative renal mass biopsy change clinical practice and reduce surgical intervention for small renal masses? August 12, 2021

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. August 11, 2021

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. August 11, 2021

Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma. August 10, 2021

Impact of Histology and Tumor Grade on Clinical Outcomes Beyond 5 Years of Follow-Up in a Large Cohort of Renal Cell Carcinomas. August 10, 2021

Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line. August 9, 2021

Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. August 9, 2021

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. August 6, 2021

Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer. August 6, 2021

Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. August 5, 2021

Nephrometric score based on 3D modeling (3D nephrometry score) for the probability prediction of intra- and postoperative complications for kidney surgery. August 5, 2021

Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. August 4, 2021

Metastatic clear cell renal cell carcinoma: computed tomography texture analysis as predictive biomarkers of survival in patients treated with nivolumab. August 4, 2021

Perioperative impact of body mass index on upper urinary tract and renal robot-assisted surgery: a single high-volume centre experience. August 3, 2021

Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions. August 3, 2021

Page 96 of 456